Treatment Strategy: Stem Cell Transplant

For children with Cernunnos-XLF deficiency, a Hematopoietic Stem Cell Transplant (HSCT)—sometimes called a bone marrow transplant—is the only established potentially curative treatment for the severe immune defect ^[1][2]. The goal of the transplant is to replace your child’s stem cells, which carry the pathogenic variant, with healthy donor cells that can correctly repair DNA and build mature T-cells and B-cells ^[3].

Why Individualized Conditioning Matters

Before a transplant can happen, the child must undergo conditioning. This process uses chemotherapy or immunosuppressive medicines to create space in the bone marrow and suppress the child’s immune system to prevent it from rejecting the new donor cells.

In many conditions, doctors use myeloablative conditioning (MAC), which is very intense. However, because children with Cernunnos-XLF have cellular radiosensitivity, their bodies cannot repair the profound DNA damage caused by these standard treatments ^[4][5].

• High Toxicity Risk: In a multicenter study of DNA-repair disorders, survival was lower for those who received intense myeloablative conditioning because the treatments were too toxic for their sensitive bodies ^[1].
• The RIC Approach: Instead, experts prefer individualized Reduced-Intensity Conditioning (RIC) regimens ^[1]. This approach uses lower doses of chemotherapy to balance the need for the new cells to grow (engraftment) while attempting to minimize the life-threatening side effects of DNA damage ^[6][5].
• Not Risk-Free: Reduced intensity does not mean low risk. It may still cause organ toxicity, graft failure, or graft rejection, and the specific drugs are highly individualized based on genotype, infection status, and the donor source.

What a Transplant Can and Cannot Fix

It is important to have a clear understanding of what this treatment achieves. A successful transplant is life-changing, but it is not a cure for the non-blood tissues of the body.

• What it Fixes: A successful transplant reconstitutes the blood and immune system ^[1]. This means your child can eventually make their own T-cells and B-cells, allowing them to fight off infections and, in many cases, eventually live without the need for lifelong protective isolation ^[2][1].
• What it Does NOT Fix: Because Cernunnos-XLF is a systemic disorder (meaning it affects the DNA in every cell of the body), replacing the blood-building cells does not change the DNA in the brain, skin, or bones. Features like microcephaly (small head size), growth retardation, and the body’s general cellular radiosensitivity remain after a transplant ^[1][7].

Success Rates and Risks

Because the condition is so rare, doctors look at data from pooled cohorts of similar DNA-repair disorders.

• Survival: In a multicenter study of 77 patients with various DNA-repair defects (including XLF), the overall survival rate was approximately 69% ^[1]. Most deaths occurred early in the process, often due to infections or organ toxicity from the conditioning drugs.
• Graft-Versus-Host Disease (GVHD): This is a complication where the new donor cells see the child’s body as “foreign” and attack it. In the study mentioned above, about 49% of patients experienced acute GVHD ^[1]. Other relevant risks include chronic GVHD, serious infections, organ toxicity, and potential impacts on future fertility. Outcomes vary substantially based on age, donor match, and clinical status.

Timing and Expertise

Because infections can happen quickly and be very dangerous, many specialists recommend evaluating for a transplant early. Waiting until a child is very sick with an infection can make the transplant process much riskier ^[8][9].

Your child must be cared for by a specialized pediatric immunology-transplant team. A typical transplant timeline involves a donor search, pretransplant evaluation, several days of individualized conditioning, stem-cell infusion (Day 0), followed by a highly vulnerable engraftment waiting period, discharge, and intensive early follow-up ^[10][11].